ArticleOncogene2022

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.

Shanade Dunn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.